Q-VD-OPh: Irreversible Pan-Caspase Inhibitor for Apoptosis Research

Executive Summary: Q-VD-OPh (CAS 1135695-98-5) is a highly potent, irreversible pan-caspase inhibitor with cell- and brain-permeable properties, enabling effective blockade of caspase-1, -3, -8, and -9 at nanomolar concentrations (Conod et al., 2022). It is widely applied in apoptosis research to dissect programmed cell death in human, mouse, and rat models. Q-VD-OPh demonstrates superior performance in preserving cell viability post-cryopreservation, maintaining stability in DMSO and ethanol but not water. In vivo, intraperitoneal administration at 10 mg/kg three times weekly mitigates pathological tau changes in Alzheimer's models (APExBIO). The compound is supplied as a solid and is intended exclusively for scientific research applications.

Biological Rationale

Apoptosis, or programmed cell death, is a fundamental biological process crucial for development, tissue homeostasis, and elimination of damaged cells. Central to this process are caspases, a family of cysteine proteases responsible for orchestrating cell dismantling. Dysregulation of caspase activity is implicated in diseases such as cancer, neurodegeneration, and immune disorders (Conod et al., 2022). Inhibition of caspase-mediated pathways allows researchers to dissect the role of apoptosis in health and disease, and to model the effects of cell death blockade in vitro and in vivo. Pan-caspase inhibitors like Q-VD-OPh provide a targeted means to prevent the activation of multiple caspases simultaneously, supporting studies on cell survival, regeneration, and disease progression (see review).

Mechanism of Action of Q-VD-OPh

Q-VD-OPh is an irreversible, broad-spectrum caspase inhibitor. It covalently modifies the active site cysteine of target caspases, rendering them catalytically inactive. The compound inhibits caspase-3 (IC₅₀ ≈ 25 nM), caspase-1 (IC₅₀ ≈ 50 nM), caspase-8 (IC₅₀ ≈ 100 nM), and caspase-9 (IC₅₀ ≈ 430 nM) under cell-free assay conditions. Its cell-permeable and brain-permeable nature enables effective intracellular access in mammalian cells, including neurons. Q-VD-OPh blocks both intrinsic (mitochondrial, caspase-9/3) and extrinsic (death receptor, caspase-8/10) apoptotic pathways, as well as ER-stress-mediated apoptosis (caspase-12) (Conod et al., 2022). Irreversible inhibition distinguishes Q-VD-OPh from reversible caspase inhibitors, conferring sustained pathway blockade even after compound washout (further analysis).

Evidence & Benchmarks

• Q-VD-OPh prevents caspase-3 activation and subsequent DNA fragmentation in staurosporine-induced apoptosis models (Conod et al., 2022, DOI).
• In human colon cancer cells, Q-VD-OPh blocks apoptosis and allows cells to acquire pro-metastatic states post-near-death (Conod et al., 2022, DOI).
• Intraperitoneal administration of 10 mg/kg Q-VD-OPh three times weekly for three months inhibits caspase-7 activation and reduces pathological tau in mouse Alzheimer’s models (APExBIO product data).
• Q-VD-OPh maintains cell viability during thawing from cryopreservation in standard cryoprotectant media (APExBIO data sheet: A1901 kit).
• Compound is soluble ≥25.67 mg/mL in DMSO and ≥28.75 mg/mL in ethanol, but insoluble in aqueous buffers (APExBIO technical specification: product page).

This article extends the mechanistic discussion presented in Strategic Caspase Inhibition in Translational Research by providing quantitative benchmarks and practical workflow parameters for Q-VD-OPh.

Applications, Limits & Misconceptions

Q-VD-OPh is widely used to study apoptosis in mammalian cell lines, primary cells, and animal models. It is particularly valuable for:

• Dissecting caspase signaling pathway roles in programmed cell death.
• Enhancing post-cryopreservation cell viability in sensitive cell types.
• Neurodegenerative disease research, especially Alzheimer's pathology modeling.
• Investigating ER-stress apoptosis and metastatic reprogramming (Conod et al., 2022).

It is distinct from reversible inhibitors due to its covalent and irreversible action, which supports long-term studies of cell fate post-apoptosis blockade (compare review—this article provides updated solubility and handling guidelines).

Common Pitfalls or Misconceptions

• Not effective in water: Q-VD-OPh is insoluble in aqueous solutions; always dissolve in DMSO or ethanol at ≥25.67 mg/mL or ≥28.75 mg/mL, respectively (APExBIO).
• Not a diagnostic or therapeutic agent: Q-VD-OPh is for research use only; it is not approved for clinical, diagnostic, or medical applications.
• Long-term solution storage: Stock solutions are stable for several months below -20°C, but long-term storage is discouraged due to potential degradation (technical guidelines).
• Broad inhibition may mask pathway specificity: Pan-caspase inhibition can obscure the roles of individual caspases; use with controls for pathway mapping (see related article; this article details limitations in single-caspase studies).
• Not effective after irreversible cell damage: In cells beyond the point of no return (late apoptosis/necrosis), Q-VD-OPh cannot restore viability.

Workflow Integration & Parameters

Q-VD-OPh is supplied as a crystalline solid by APExBIO (SKU A1901), shipped with blue ice. For in vitro assays, dissolve in DMSO or ethanol to obtain a ≥25 mg/mL stock. Use working concentrations in the 10–100 µM range, depending on cell type and target caspase profile. For in vivo use, administer intraperitoneally at 10 mg/kg, three times weekly, as validated in Alzheimer's studies (product protocol). Avoid repeated freeze-thaw cycles. Q-VD-OPh’s cell- and brain-permeability facilitate its application in CNS and peripheral models. Reference controls (e.g., vehicle, single-caspase inhibitors) are recommended to interpret pathway specificity.

This article clarifies and updates workflows specified in Q-VD-OPh: Redefining Caspase Inhibition for Advanced Cell Models by providing precise solubility, dosing, and storage parameters.

Conclusion & Outlook

Q-VD-OPh is a benchmark tool in apoptosis research, enabling robust, irreversible inhibition of caspase activity in vitro and in vivo. Its superior cell-permeability and potency distinguish it from prior-generation caspase inhibitors. The product’s validated use in Alzheimer’s disease models and cell viability preservation post-cryopreservation highlight its translational potential. Future work will clarify the role of pan-caspase inhibition in regenerative medicine and metastasis prevention. For comprehensive technical details and ordering, see the APExBIO Q-VD-OPh product page.